Clinical Trial Update: Study in Intensive Care Patients to Investigate the Clinical Effect of Repetitive Orally Inhaled Doses of AP301 on Alveolar Liquid Clearance in Acute Lung Injury [Phase 2]

View source ↗

Summary

Phase 2 clinical trial updating results for repetitive orally inhaled AP301 in acute lung injury to assess alveolar liquid clearance in intensive care patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Injury

Drugs mentioned

• AP301

Snippet

Sponsor: Apeptico Forschung und Entwicklung GmbH | Conditions: Acute Lung Injury | Phase 2 | Status: COMPLETED